Coexistence of antiphospholipid antibodies and cephalalgia

Cephalalgia. 2018 Mar;38(3):568-580. doi: 10.1177/0333102417694881. Epub 2017 Feb 20.

Abstract

Background The occurrence of antiphospholipid antibodies (aPLs) and headache comorbidity in the presence or absence of underlying autoimmune diseases remains unclear. Aim The aim of this review was to summarize the relationship between headache and aPLs based on evidences from cohort studies and case reports, in addition to examining the treatment strategies that resolved headache in aPLs-positive individuals. Methods A comprehensive literature search was conducted through PubMed, ISI Web of Science and Google Scholar. A total of 559 articles were screened and the appropriate articles were selected based on quality and level of evidence. Results Cohort studies (n = 27) from Europe, North America and Asia demonstrated comorbidity of aPLs and headache in antiphospholipid syndrome, systemic lupus erythematosus (SLE) and neuropsychiatric SLE patients. Significantly higher association between migraine and aPLs was observed (n = 170/779; p < 0.0001) in individuals without any underlying diseases. Our analysis of shortlisted case reports (n = 17) showed that a higher frequency of anticardiolipin antibodies were present in subjects with different autoimmune disorders (70.6%). Corticosteroids were highly effective in resolving headache in aPLs-positive individuals. Conclusion Higher frequency of comorbidity between aPLs and headache was observed in healthy individuals and patient cases. Therefore, experimental studies are warranted to evaluate the aPLs-induced pathogenic mechanism of headache.

Keywords: Lupus anticoagulant; anti-β2GPI antibodies; anticardiolipin antibodies; headache; migraine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Antibodies, Antiphospholipid / blood*
  • Antiphospholipid Syndrome / epidemiology
  • Comorbidity
  • Female
  • Headache / blood*
  • Headache / complications
  • Headache / immunology*
  • Humans
  • Lupus Erythematosus, Systemic / epidemiology
  • Male
  • Middle Aged

Substances

  • Antibodies, Antiphospholipid